Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38965   clinical trials with a EudraCT protocol, of which   6398   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-003158-18
    Sponsor's Protocol Code Number:203PF203
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2020-11-05
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2017-003158-18
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
    Studio randomizzato, in doppio cieco, controllato con placebo per valutare l’efficacia e la sicurezza di BG00011 in pazienti affetti da fibrosi polmonare idiopatica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis
    Valutazione l’efficacia e la sicurezza di BG00011 in pazienti affetti da fibrosi polmonare
    A.3.2Name or abbreviated title of the trial where available
    Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis
    Valutazione dell’efficacia e la sicurezza di BG00011 in pazienti affetti da fibrosi polmonare
    A.4.1Sponsor's protocol code number203PF203
    A.5.4Other Identifiers
    Name:NANumber:NA
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBIOGEN IDEC RESEARCH LIMITED
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Limited
    B.5.2Functional name of contact pointMedical
    B.5.3 Address:
    B.5.3.1Street AddressInnovation House, 70 Norden Road
    B.5.3.2Town/ cityMaidenhead
    B.5.3.3Post codeSL6 4AY
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number000000000000
    B.5.5Fax number0000000000000000
    B.5.6E-mailclinicaltrials@biogen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.1.1Trade name NA
    D.2.1.1.2Name of the Marketing Authorisation holderNA
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namehumanized anti-alpha v beta 6 mAb
    D.3.2Product code [BG00011]
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot yet assigned
    D.3.9.2Current sponsor codeBG00011
    D.3.9.4EV Substance CodeSUB191995
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number56
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typehumanized monoclonal antibody
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    mild to moderate Idiopathic Pulmonary Fibrosis
    fibrosi polmonare idiopatica (FPI) da lieve a moderata
    E.1.1.1Medical condition in easily understood language
    mild to moderate scarring of lung tissue
    cicatrici da lievi a moderate del tessuto polmonare
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10021240
    E.1.2Term Idiopathic pulmonary fibrosis
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of BG00011 compared with placebo in subjects with Idiopathic pulmonary fibrosis (IPF).
    valutare l’efficacia di BG00011 rispetto al placebo in soggetti affetti da FPI.
    E.2.2Secondary objectives of the trial
    To evaluate
    -The efficacy of BG00011 compared with placebo in subjects with IPF as determined by change in percent predicted FVC
    -The safety and tolerability of BG00011; and to evaluate the serum concentration of BG00011
    To assess
    -Progression-free survival in subjects who receive BG00011 compared with placebo.
    -The occurrence of IPF exacerbation in participants who receive BG00011 compared with placebo
    -The incidence of absolute decline in FVC =10% in subjects who receive BG00011 compared with placebo.
    -The time to death or lung transplantation in subjects who receive BG00011 compared with placebo, and the transplant-free survival rate at Week 26 and Week 52
    -The time to nonselective hospitalizations in subjects who receive BG00011 compared with placebo.
    -Additional PFT findings in subjects who receive BG00011 compared with placebo
    - Performance on the 6MWT in participants who receive BG00011 compared with placebo
    Please refer to protocol for further secondary objectives
    Per valutare
    - l’efficacia di BG00011 rispetto al placebo in soggetti affetti da FPI, come determinato dal cambiamento di FVC predetto in percentuale.
    - la sicurezza e la tollerabilità di BG00011; e di Valutare la concentrazione sierica di BG00011
    - la sopravvivenza libera da progressione in soggetti che ricevono BG00011 rispetto al placebo.
    - Valutare l’occorrenza dell’esacerbazione della FPI in soggetti che ricevono BG00011 rispetto al placebo.
    - l’incidenza del declino assoluto di FVC >=10% in soggetti che ricevono BG00011 rispetto al placebo.
    - il tempo al decesso o al trapianto del polmone in soggetti che ricevono BG00011 rispetto al placebo e il tasso di sopravvivenza libera da trapianto alla Settimana 26 e alla Settimana 52.
    - il tempo di ricovero obbligatorio in soggetti che ricevono BG00011 rispetto al placebo.
    - i risultati degli ulteriori test di funzionalità polmonare (PFT) in soggetti che ricevono BG00011 rispetto al placebo.
    - la prestazione del test del camm
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Female subjects must be surgically sterile,
    postmenopausal (minimum 1 year without menses), or
    agree to use 1 or more forms of highly effective
    contraception from the time of signing of the informed
    consent form (ICF) until 3 months after the last injection
    of study medication. Male subjects must also agree to
    use 1 or more forms of highly effective contraception for
    either themselves or their partners from signing of ICF
    until 4 months after last injection of study medication.
    - Diagnosed with Idiopathic pulmonary fibrosis (IPF).
    - Combination of high-resolution computed tomography
    (HRCT) pattern and, if one has been obtained, surgical
    lung biopsy pattern, consistent with diagnosis of IPF.
    - Carbon monoxide diffusion capacity (DLco) (corrected
    for hemoglobin): 30% to 79% predicted of normal at
    Screening, with no clinically significant deterioration
    between the Screening Visit and randomization, as
    determined by the Investigator.
    - Forced (expiratory) vital capacity (FVC) >=50%
    predicted of normal at Screening, with no clinically
    significant deterioration between the Screening Visit and
    randomization, as determined by the Investigator.
    - If a subject is taking nintedanib or pirfenidone, they
    must be on a stable dose for at least 8 weeks prior to
    randomization.
    NOTE: Other protocol defined inclusion criteria may apply.
    - I soggetti di sesso femminile devono essere chirurgicamente sterili, in postmenopausa (minimo 1 anno senza mestruazioni) oppure devono accettare di utilizzare 1 o più metodi di contraccezione altamente efficaci dal momento della firma del modulo di consenso informato (ICF) fino a 3 mesi dopo l’ultima iniezione del farmaco dello studio. Anche i soggetti di sesso maschile devono accettare di utilizzare 1 o più metodi di contraccezione altamente efficaci per se stessi o per le loro partner dalla firma dell’ICF fino a 4 mesi dopo l’ultima iniezione del farmaco dello studio.
    - Diagnosi di fibrosi polmonare idiopatica (FPI).
    - Combinazione di un modello di tomografia computerizzata ad alta risoluzione (HRCT) e, se è stato acquisito, di un modello di biopsia polmonare chirurgica, coerenti con la diagnosi di FPI.
    - Capacità di diffusione del monossido di carbonio (DLco) (corretta per l’emoglobina): prevista essere dal 30% al 79% del valore normale allo screening, senza deterioramento clinicamente significativo tra la visita di screening e la randomizzazione, come stabilito dallo sperimentatore.
    - Capacità vitale forzata (espiratoria) (CVF) prevista essere >=50% del valore normale allo screening, senza deterioramento clinicamente significativo tra la visita di screening e la randomizzazione, come stabilito dallo sperimentatore.
    - Se un soggetto sta assumendo nintedanib o pirfenidone, questi devono essere a dose stabile per almeno 8 settimane prima della randomizzazione.

    NOTA: possono essere applicati altri criteri di inclusione definiti dal protocollo.
    E.4Principal exclusion criteria
    - Unable to perform pulmonary functional tests (PFTs) or
    undergo HRCT procedure.
    - Peripheral capillary oxygen saturation (SpO2) <90% at
    rest (if on oxygen supplementation, must be =2 L/min at
    rest).
    - Airway obstruction (i.e., prebronchodilator FEV1/FVC
    <0.7) or evidence of a bronchodilator response as
    defined by an absolute increase of =12% and an
    increase of =200 milliliters (mL) in FEV1 or FVC, or both,
    after bronchodilator use, compared with the values
    before bronchodilator use at Screening.
    - End-stage fibrotic disease likely requiring organ
    transplantation within 12 months, or if the subject has
    initiated active evaluation for organ transplantation.
    - The extent of emphysema in the lungs exceeds
    fibrosis, based on central review of HRCT
    scans.
    - Body weight <60 kg at Screening.
    - History of or ongoing malignant disease, including solid
    tumors and hematologic malignancies, with the
    exception of basal cell carcinomas, squamous cell
    carcinomas, and carcinoma in situ of the cervix that
    have been completely excised and considered cured >2
    years prior to Screening.
    - Significant cardiac disease (e.g., New York Heart
    Association Class 3 or 4; myocardial
    infarction within the past 6 months; unstable angina;
    coronary angioplasty or coronary artery bypass graft
    within the past 6 months; uncontrolled atrial or
    ventricular cardiac arrhythmias; or pulmonary
    hypertension requiring pharmacologic treatment).
    - Clinical diagnosis of any connective tissue disease
    (including but not limited to scleroderma,
    polymyositis/dermatomyositis, systemic lupus
    erythematosus, and rheumatoid arthritis) or a diagnosis
    of interstitial pneumonia with autoimmune features as
    determined by the Investigator.
    - Other disease that may interfere with testing
    procedures or, in the judgment of the Investigator, may
    interfere with study participation or may put the patient
    at risk when participating in this study.
    - Other unspecified reasons that, in the opinion of the
    Investigator or Biogen, make the subject unsuitable for
    enrollment.
    NOTE: Other protocol defined exclusion criteria may apply.
    - Soggetto non in grado di eseguire i test di funzionalità polmonare (PFT) o di sottoporsi alla procedura di HRCT.
    - Saturazione dell’ossigeno a livello capillare periferico (SpO2) <90% a riposo (se in ossigenoterapia, deve essere <=2 l/min a riposo).
    - Ostruzione delle vie aeree (per es., volume espiratorio massimo in 1 secondo [VEMS]/CVF pre-broncodilatatore <0,7) o evidenza di risposta del broncodilatatore definita come un aumento assoluto >=12% e un aumento >=200 millilitri (ml) in VEMS o CVF, o entrambi, dopo l’utilizzo del broncodilatatore, rispetto ai valori precedenti all’utilizzo del broncodilatatore allo screening.
    - Malattia fibrotica in fase terminale che può richiedere un trapianto di organi entro i 12 mesi, oppure nel caso in cui il soggetto abbia iniziato una valutazione attiva per il trapianto di organi.
    - L’estensione dell’enfisema nei polmoni supera quello della fibrosi, sulla base di un esame centrale delle scansioni HRCT.
    - Peso corporeo <60 kg allo screening.
    - Anamnesi di o malattia maligna in corso, compresi tumori solidi e neoplasie ematologiche maligne, ad esclusione del carcinoma a cellule basali, del carcinoma a cellule squamose e del carcinoma in situ della cervice che sono stati completamente escissi e sono considerati guariti per >2 anni prima dello screening.
    - Malattia cardiaca significativa (per es., classe 3 o 4 secondo la New York Heart Association [Associazione cardiologica di New York]; infarto miocardico negli ultimi 6 mesi; angina instabile; angioplastica coronarica o bypass aorto-coronarico negli ultimi 6 mesi; aritmie cardiache atriali o ventricolari non controllate; oppure ipertensione polmonare che richiede un trattamento farmacologico).
    - Diagnosi clinica di una qualsiasi malattia del tessuto connettivo (tra cui, senza limitazioni, sclerodermia, polimiosite/dermatomiosite, lupus eritematoso sistemico e artrite reumatoide) oppure diagnosi di polmonite interstiziale con caratteristiche autoimmuni, come stabilito dallo sperimentatore.
    - Altre malattie che possono interferire con le procedure dei test o che, a giudizio dello sperimentatore, possono interferire con la partecipazione allo studio o che possono mettere il paziente a rischio durante la partecipazione allo studio.
    - Altri motivi non specificati, secondo il parere dello sperimentatore
    E.5 End points
    E.5.1Primary end point(s)
    Yearly Rate of Change in Forced (Expiratory) Vital Capacity (FVC)
    Tasso di variazione annuale della capacità vitale forzata (espiratoria) (CVF)
    E.5.1.1Timepoint(s) of evaluation of this end point
    various time point assessments throughout the study
    varie valutazioni del punto di rilevazione durante lo studio
    E.5.2Secondary end point(s)
    Percent Predicted Yearly Rate of Change in FVC - Time to Progression - Time to First Acute Exacerbation - Percentage of Participants with at least 1 Acute Exacerbation - Number of Exacerbations - Number of Participants with Absolute Decline of 10% Predicted in FVC - Time to Death or Lung Transplantation - Time to All Non-Elective Hospitalizations - Time to All Non-Elective Respiratory Hospitalizations - Change from Baseline in Absolute Predicted FVC - Change from Baseline in Percent Predicted FVC - Change from Baseline in Absolute Predicted Carbon Monoxide Diffusion Capacity (DLco) - Change from Baseline in Percent Predicted Carbon Monoxide Diffusion Capacity (DLco) - Change from Baseline in Absolute Predicted Total Lung Capacity - Change from Baseline in Percent Predicted Total Lung Capacity - Change from Baseline in 6 Minute Walk Test (6MWT) Parameters - Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) - Percentage of Participants With Anti-BG00011 Antibodies in the Serum - Concentration of BG00011 in the Serum
    - Tasso di variazione annuale percentuale previsto nella CVF
    - Tempo alla progressione
    - Tempo alla prima riacutizzazione acuta
    - Percentuale di partecipanti con almeno 1 riacutizzazione acuta
    - Numero di riacutizzazioni
    - Numero di partecipanti con una diminuzione assoluta prevista del 10% nella CVF
    - Tempo al decesso o al trapianto polmonare
    - Tempo a tutti i ricoveri d’urgenza
    - Tempo a tutti i ricoveri d’urgenza per problemi respiratori
    - Variazione dal basale nella CVF assoluta prevista
    - Variazione dal basale nella CVF percentuale prevista
    - Variazione dal basale nella capacità di diffusione del monossido di carbonio (DLco)
    assoluta prevista
    - Variazione dal basale nella capacità di diffusione del monossido di carbonio (DLco)
    percentuale prevista
    - Variazione dal basale nella capacità polmonare totale assoluta prevista
    - Variazione dal basale nella capacità polmonare totale percentuale prevista
    - Variazione dal basale nei parametri del test del cammino in 6 minuti (6MWT)
    - Percentuale dei partecipanti con eventi avversi (AE) ed eventi
    avversi gravi (SAE)
    - Percentuale di partecipanti con anticorpi anti-BG00011 nel siero
    - Concentrazione sierica di BG00011
    E.5.2.1Timepoint(s) of evaluation of this end point
    Change to baseline, weeks 26 and 52
    Modifica al baseline, settimana 26 e 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA45
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Austria
    Belgium
    Canada
    Czechia
    Denmark
    France
    Germany
    Greece
    Israel
    Italy
    Korea, Republic of
    Netherlands
    Poland
    Russian Federation
    Spain
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study is last subject, last visit.
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months37
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months37
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 87
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 203
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 93
    F.4.2.2In the whole clinical trial 290
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal treatment
    Normal treatment
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-09-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-06-18
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA